ArticleOncotarget2017

Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone.

Kai-Jie Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.